(R)-4-(biphenyl-4-ylsulfonyl)-1-hydroxy-3-isopropylpiperazine-2,6-dione | 1203835-07-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-4-(biphenyl-4-ylsulfonyl)-1-hydroxy-3-isopropylpiperazine-2,6-dione
• 英文别名: (3R)-1-hydroxy-4-(4-phenylphenyl)sulfonyl-3-propan-2-ylpiperazine-2,6-dione
• CAS: 1203835-07-7
• 化学式: C₁₉H₂₀N₂O₅S
• 分子量: 388.444
• InChiKey: JVBFGGAYMSJQBZ-GOSISDBHSA-N

物化性质

• 熔点：
  164-165 °C
• 沸点：
  586.7±60.0 °C(predicted)
• 密度：
  1.371±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  D-缬氨酸 在 N-甲基吗啉 、 palladium 10% on activated carbon 、 氢气 、 氯甲酸乙酯 、 potassium carbonate 、 三乙胺 、 三氟乙酸 、 potassium iodide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 20.0 ℃ 、150.0 kPa 条件下， 反应 4.0h， 生成 (R)-4-(biphenyl-4-ylsulfonyl)-1-hydroxy-3-isopropylpiperazine-2,6-dione
  参考文献：
  名称：

  Novel 1-Hydroxypiperazine-2,6-diones as New Leads in the Inhibition of Metalloproteinases

  摘要：

  New compounds containing a novel zinc-binding group (1-hydroxypiperazine-2,6-dione, HPD) have been identified as effective inhibitors of matrix metalloproteinases (MMPs), with activities in the nanomolar concentration range. That moiety seemed to bind the catalytic zinc ion of MMPs, revealing itself as a new potential substitute for the hydroxamate group in the next generation of metalloproteinase inhibitors. The X-ray crystal structure of 1b elucidated its 3D conformation and supramolecular packing in solid state. Theoretical procedures were used to investigate the binding mode of this class of compounds, within the active site of MMP13. A computational method involving docking and hybrid quantum mechanical and molecular mechanical (QM/MM) dynamic simulations was developed and applied. This study suggested that the HPD moiety binds bidentately to the catalytic zinc through its oxygen atoms. The final structure obtained will allow straightforward drug design approaches in view of further optimization and development of new MMP inhibitors bearing the HPD moiety.

  DOI：

  10.1021/jm200593b